Physician profile
David Snelson
NPI 1497851950
$365.91
in general payments reported to CMS, 2019-2025
14 companies · $92.52 in 2025
The $92.52 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.41 · 2020: $26.01 · 2022: $19.30 · 2023: $35.77 · 2024: $105 · 2025: $92.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.67 | 2024-2025 | Caplyta |
| Noven Therapeutics, LLC | $40.21 | 2023-2024 | Xelstrym |
| Neurocrine Biosciences, INC. | $36.50 | 2024 | Ingrezza |
| Collegium Pharmaceutical, INC. | $30.17 | 2025 | Jornay Pm |
| Allergan, INC. | $27.18 | 2019-2020 | |
| Shire North American Group INC | $26.74 | 2019 | |
| Lundbeck LLC | $22.88 | 2019 | |
| Corium, LLC | $19.30 | 2022 | |
| Owp Pharmaceuticals, INC. | $18.65 | 2024 | Subvenite |
| Ironshore Pharmaceuticals INC. | $15.11 | 2023 | Jornay Pm |
| Almatica Pharma LLC | $14.88 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.00 | 2019 | |
| Tris Pharma INC | $12.16 | 2019 | |
| Adlon Therapeutics L.P. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.